Company intelligence / Profile preview
Qu Biologics
- Ownership
- Private
- Employees
- ~11
- Development stage
- Other
Overview
Qu Biologics has completed four Phase 2 clinical trials in lung cancer, Crohn’s disease and ulcerative colitis. Two additional randomized placebo-controlled Phase 2 studies are currently enrolling—one targeting post-surgical immune suppression in late-stage colon cancer patients undergoing resection of liver metastases and another evaluating restoration of innate immunity to prevent infections and improve health status in people aged ≥65. Recent results highlight efficacy signals such as improved fatty liver disease outcomes and enabling CAR T-cell efficacy against solid tumors.
- Therapeutic areas
- GastroenterologyOncologyInfectious DiseasesMetabolic Disorders
- Modalities
- Site Specific Immunomodulators (SSIs)immunotherapiesimmunomodulators
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Qu Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qu Biologics.